Statues of food-derived glutathione in intestine, blood, and liver of rat

Hiroaki Yamada, Shinn Ono, Sayori Wada, Wataru Aoi, Eun Young Park, Yasushi Nakamura and Kenji Sato

Oral administration of glutathione has been demonstrated to reduce exercise-induced fatigue and improve liver function, although glutathione can be synthesized in the liver. However, little is known about the underlying mechanism of this effect. To address this, the status of food-derived glutathione in the intestine, blood, and liver was examined. Glutathione-1,13C or N-acetyl-cysteine-1,13C (NAC) was orally administered to rats (50 mg/kg). Food-derived glutathione contents within tissues were estimated by subtracting endogenous glutathione-1,13C from the total glutathione-1,13C. Food-derived glutathione was present in rat intestines and livers (approximately 60 and 300 μmol/kg, respectively, 120 min after ingestion) in electrochemically reduced form, while all food-derived glutathione in the blood was conjugated with proteins and low-molecular-weight thiol compounds. However, no significant amounts of NAC-derived glutathione were detected in the blood plasma. These findings indicate that food-derived glutathione is directly absorbed in its electrochemically reduced form in the intestine, is then transported in the blood in bound forms, and is finally deposited into the liver in reduced form. Therefore, upon entering the bloodstream, food-derived glutathione binds to thiol compounds and releases hydrogen atom; subsequently, it does the reverse upon incorporation into the liver, which might impact the physiological redox condition. With respect to food-derived glutathione and cysteine-containing peptides, this study provides new insights on their modes of transportation and mechanisms of action.

npj Science of Food (2018) 2:3 ; doi:10.1038/s41538-018-0011-y

INTRODUCTION
Glutathione (γ-L-glutamyl-L-cysteinyl-glycine) is widely distributed in known life forms, from single-cell organisms to higher vertebrates, and is the most prevalent intracellular thiol.1,2 Glutathione is also a cofactor or substrate of glutathione peroxidase and glutathione S-transferase. Glutathione peroxidase catalyzes the reduction of hydrogen peroxide and lipid peroxides into water and hydroxyl lipids, respectively, along with the oxidation of glutathione (reduced-form) into glutathione disulfide. Glutathione peroxidase plays a crucial role in maintaining proper physiological redox conditions and protecting proteins, lipids, and nucleic acids from oxidative stress. Glutathione is regenerated from glutathione disulfide by the enzyme glutathione reductase. Glutathione-S-transferase catalyzes the conjugation of glutathione and a wide variety of electrophilic compounds (both endogenous and exogenous): this is the first step in the mercapturic acid pathway, a crucial component of system detoxification.

Glutathione can be synthesized in the cells via a two-step ATP-dependent enzymatic process; the first step is conjugation of glutamic acid and cysteine, which is catalyzed by glutamate-cysteine ligase and generates γ-glutamyl-cysteine (γ-Glu-Cys) and the second step is catalyzed by glutathione synthase, which adds glycine to γ-Glu-Cys, forming glutathione.1,2 Glutathione is present in many foods and has been produced by fermentation to be used as supplement for whitening the skin, moderating fatigue, and improving liver functions in some countries. Oral administration of glutathione in the treatment group has been reported to reduce melanin indices on the skin3 and exercise-induced fatigue compared to that in the placebo controls.4 Recently, oral administration of glutathione has been demonstrated to significantly reduce plasma aminotransferase and free fatty acid levels of patients with non-alcoholic fatty liver disease.5 These studies suggested that oral administration of glutathione was beneficial. Another study in humans demonstrated that dietary supplementation of glutathione resulted in an increase in protein-bound glutathione in the blood plasma,6 indicating that glutathione in foods and supplements can affect the blood glutathione level. However, glutathione doses used in these human trials were not that high (300–1000 mg/day). Small pieces (10–50 g) of meats, eggs, fish, and other animal foods generally contain sulfur-containing amino acids equivalent to cysteine in 300 mg glutathione. Therefore, ingestion of 300 mg of glutathione unlikely provides beneficial effects on liver function by only supplying glutathione or its precursor cysteine. However, glutathione can bind to thiol groups of protein and other low-molecular-weight compounds. Conversion between bound- and free-form glutathione releases and receives hydrogen atom and thiol compounds, respectively, which may induce physiological responses. However, the status of food-derived glutathione in hepatic portal blood—and upon its deposition into the target organ such as the liver—remain poorly understood.

The objectives of this study were to confirm the deposition of food-derived glutathione in the rat liver and to determine the status of food-derived glutathione in the intestines, blood, and liver of rat.
liver using stable-isotope-labeled glutathione-1-13C and N-acetylcycteine-1-13C to better understand the mechanisms for beneficial effects of oral glutathione administration.

RESULTS AND DISCUSSION
Presence of food-derived glutathione in the body
Our previous study demonstrated that protein-bound glutathione in human plasma increases after ingestion of glutathione. However, whether the increased glutathione levels were directly derived from the ingested glutathione or synthesized from endogenous sources remains unclear.

To detect food-derived glutathione, all forms of food-derived glutathione were converted to a double conjugate with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AccQ) and 2-mercaptoethanol. As shown in Fig. 1, after ingestion of glutathione-1-13C, food-derived glutathione was detected in the intestine (approximately 60 μmol/kg at 120 min), liver (approximately 300 μmol/kg at 120 min), and blood plasma (both in low-molecular-weight and protein-bound fractions) of experimental rats. The difference between total glutathione as AccQ-2-mercaptoethanol double conjugate and reduced-form glutathione in the intestines and liver was insignificant, indicating that most of the food-derived glutathione in the intestine and liver were in the reduced form (Figs. 1 and 2). In the previous study, food-derived glutathione disulfide was, however, detected in liver and blood red cell of mice. However, blood in the liver used in the previous study was not purged. Then, the glutathione disulfides in the mice liver might be derived from the red cell. In the intestines and liver, only negligible amounts of food-derived cysteynlglycine (Cys-Gly) and gamma-glutamyl-cysteine (γ-Glu-Cys), (a glutathione-degradation product and a precursor of glutathione, respectively) were detected, while significant amounts of food-derived Cys-Gly and γ-Glu-Cys were detected in the plasma. After ingestion of N-acetylcysteine-1-13C (NAC), food-derived glutathione was also present in the intestines and liver, indicating that NAC can be used for glutathione synthesis in these organs (Fig. 1b), whereas NAC-derived glutathione and its fragment peptides were not detected in the plasma. Then, at least within 120 min, the endogenously synthesized glutathione in intestinal and liver cells was not excreted into the bloodstream. The presence of food-derived glutathione in the portal blood after

![Fig. 1](image-url) Total food-derived glutathione (GSH) contents in the washed intestine, liver, and low-molecular-weight (EtOH-soluble) and protein-bound fractions of blood plasma obtained from the portal and inferior vena cava. a After ingestion of stable isotope-labeled glutathione; b after ingestion of stable isotope-labeled N-acetylcysteine. Data are presented as mean ± standard deviation. * indicates significant difference compared with levels before ingestion (P < 0.05). # indicates significant difference compared with the counterpart from the inferior vena cava
ingestion of stable isotope-labeled glutathione indicates that it passes through the lining of the intestinal tract, which is consistent with our previous in vitro studies using Caco-2 cell line (a widely used model for testing the intestinal permeability of compounds) and small intestines mounted on an Ussing chamber.7

Status of food-derived glutathione in the blood plasma
Food-derived Cys-Gly and γ-Glu-Cys were detected in the blood plasma (Fig. 2a), indicating that at least a portion of food-derived glutathione is degraded by γ-glutamyltransferase or other peptidases (either circulating freely in the blood or on the surface of cell membranes) during blood circulation. As shown in Fig. 1a, 60 min after ingestion, food-derived glutathione levels in the low-molecular-weight fraction of blood from the hepatic portal vein (approximately 0.4 µM) were significantly higher (P<0.05) than those in the corresponding fraction from the inferior vena cava (<0.1 µM). The food-derived glutathione levels within the protein-bound fraction between the plasma from the portal vein and from the inferior vena cava were insigificantly different, which indicates that glutathione in the low-molecular-weight fraction may be preferentially incorporated into the liver. As shown in Fig. 3, no reduced-form glutathione and glutathione disulfide were detected in the low-molecular-weight fraction of plasma from the portal vein. These data agree with the recent studies using high-performance liquid chromatography (HPLC) coupled with electrochemical detection.6 In contrast, the presence of glutathione and its disulfide in the plasma has been suggested based on the detection of thiol group using Ellman’s reagent and glutathione reductase.7,9 However, as shown in Supplementary Figure, a couple of compounds with free thiol group and disulfide bond are present in the low-molecular-weight fraction of rat plasma, which can react with Ellman’s reagent and provide apparent values for glutathione and its disulfide. Furthermore, it has been demonstrated that glutathione reductase can react other disulfides in addition to glutathione disulfide.10 Therefore, to determine the low amounts of glutathione and its derivatives in the blood plasma, direct chromatographic separation and a specific detection method such as mass spectrometry are necessary.

The compounds in the low-molecular-weight fraction of the plasma from portal vein, which was collected 60 min after the ingestion of glutathione, were fractionated by size exclusion chromatography (SEC). As shown in Fig. 3b, upon reduction with 2-mercaptoethanol, glutathione was released between SEC fractions 37 and 41. The mass spectrometry analysis revealed that peptides with approximately 200–800 Da were eluted in these fractions. Consequently, orally administered glutathione is bound to other low-molecular-weight thiol compounds.

Incorporation of food-derived glutathione into the liver
The present study demonstrates the deposition of reduced-form food-derived glutathione in the liver (Fig. 2b). In the liver without blood, only negligible amounts of food-derived Cys-Gly, γ-Glu-Cys, and glutathione disulfide were detected. Detailed mechanism regarding the transportation of plasma bound-form glutathione into the hepatocytes remains unknown. High contents (approximately 6 mmol/kg) of endogenous reduced-form glutathione were present in the rat liver. If the plasma bound-form glutathione were to be converted to the reduced form before passing through the cell membrane, it would have to be transported into hepatocytes containing extremely higher concentrations of the same compound. This kind of transporter system is not yet known.

---

**Fig. 2** Contents of total food-derived glutathione (GSH) and its fragments, cysteinyl-glycine (CG), and gamma-glutamyl-glycine (γ-EC) in the blood plasma (a) and status of food-derived glutathione in washed intestine and liver (b). a Total glutathione and fragment peptides in low-molecular-weight (EtOH-soluble) and protein-bound fractions of the plasma 120 min after the ingestion. b Levels of total and reduced-form of glutathione in the washed intestine and liver 60 and 120 min after ingestion, respectively.
The bound-form glutathione is likely transported into the hepatocytes and then converted to the reduced form. Alternatively, the bound-form glutathione may be degraded into amino acids on the cell membrane surface and the resulting amino acids may be incorporated into the hepatocytes and then used for intracellular glutathione synthesis. In both cases, bound-form glutathione must be converted to reduced-form glutathione or cysteine on or in the hepatocytes. To elucidate the transportation system of the plasma bound-form glutathione into the hepatocytes, further studies using hepatocytes and labeled glutathione and its derivatives are ongoing.

Possible mechanism for health-promoting effects of glutathione in food
Oral administration of glutathione has been reported to increase the liver glutathione level in animals by inhibiting endogenous glutathione synthesis. The present study also demonstrates that orally administered glutathione can be physiologically reduced-glutathione and glutathione disulfide that orally administered glutathione can be physiologically reduced-form of glutathione and glutathione disulfide were detected. Detection of glutathione in size exclusion chromatography fractions of low-molecular-weight fraction of blood plasma after reduction with 2-mercaptoethanol.

Fig. 3 Status of glutathione in low-molecular-weight fraction of blood plasma obtained from the portal vein. a Detection of reduced-form of glutathione and glutathione disulfide using the LC-MS/MS in multi-reaction monitoring mode. The arrow indicates elution position of the standards. No glutathione and glutathione disulfide were detected. b Detection of glutathione in size exclusion chromatography fractions of low-molecular-weight fraction of blood plasma after reduction with 2-mercaptoethanol.

METHODS

Chemicals
Reduced form of L-glutathione was obtained from KOHJIN Life Sciences (Tokyo, Japan). Glutathione disulfide, γ-L-glutamyl-L-cysteine, L-cysteinyl-glycine, and L-cystine with 13C isotopes at C1 and C1' (L-Cystine-1,1′-13C) were purchased from Sigma-Aldrich (St. Louis, MO, USA). L-Cysteine was obtained from Wako Pure Chemicals (Osaka, Japan), 6-aminoquinolyl-N-hydroxy succinimidyl carbamate (AccQ) from Synchem (Altenburg, Germany), and the AccQ Tag Ultra Derivatization Kit from Waters (Milford, MA, USA). Acetonitrile (HPLC-grade), triethylamine, formic acid, trichloroacetic acid (TCA), 2-mercaptoethanol, and N-ethylmaleimide (NEM) were obtained from Nacalai Tesque (Kyoto, Japan). Amino acid derivatives and reagents for peptide synthesis were purchased from Watanabe Chemical (Hiroshima, Japan).

Preparation of working reagents
KH2PO4 (0.2 M) and Na2HPO4 (0.2 M) were mixed at a ratio of 40.5:9.5, (v/v), and the pH, if necessary, was adjusted to 7.4 by adding KH2PO4 or Na2PO4 (0.2 M) at a ratio of 40.5:9.5 (v/v) and used as phosphate-buffered saline (PBS). Triethylamine, methanol, and water were mixed at a ratio of 2:7:1 (v/v) that was used as an alkaline solution.
Synthesis of stable isotope-labeled glutathione

Stable isotope-labeled glutathione was synthesized by a liquid-phase method from cystine-1,13C using the disulfide bond as a thiol-protecting group. Cystine-1,13C was converted into the corresponding N,N′-tert-butylxycarbonyl (Boc) protected form using di-tert-butyl dicarbonate. The Boc-protected cystine-1,13C was reacted with two equivalents of glycine tert-butyl ester (Obu) hydrochloride using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide monohydrochloride and 1-hydroxybenzotriazole to produce the N and C-protected dipeptidyl (Boc-Cys-Gly-Obu) disulfide derivative. Cleavage of Boc groups with 4 M HCl/dioxane followed by a coupling reaction with the γ-carboxyl group of the N-hydroxy succinimidyl active ester of Boc-Glu-Obu resulted in the corresponding glutathione disulfide-1,13C with fully protected N and C-terminals; glutathione disulfide-1,13C was prepared by deposition with TFA. Glutathione-1,13C was obtained by reduction with diethylthreothitol (DTT) in an aqueous solution. Finally, the obtained crude product was purified by preparative reversed-phase HPLC using a Cosmosil 5C18-AR-II (20 mm i. d. × 250 mm; Nacalai Tesque). The corresponding fraction was lyophilized, giving 169 mg of the desired product in 41% yield. The final product was characterized by analytical reversed-phase HPLC using a TSKgel ODs-100S (3.0 mm i.d. × 150 mm; Tosoh, Tokyo Japan) and electrospray ionization time-of-flight mass spectrometry with a Hitachi Nano Frontier liquid chromatography-mass spectrometry (LC-MS) system (Tokyo, Japan).

Preparation of stable isotope labeled N-acetylcysteine (NAC)

NAC-1,13C was synthesized from cystine-1,13C. The amino group of cystine-1,13C was reacted with acetic anhydride to produce its acetylated derivative. NAC-1,13C was released by reduction with DTT and purified by the preparative reversed-phase HPLC as described above. The final product (698 mg) was obtained in 54% yield and characterized by the analytic reversed-phase HPLC and 1H NMR with a JEOL JNA-ECSX50 spectrometer (Tokyo, Japan). Each analytical result was consistent with the proposed structure.

Animal experiments

All animals were treated and cared in accordance with the National Institutes of Health’s guidelines for the use of experimental animals. All experimental procedures were approved by the Animal Care Committee of Kyoto Prefectural University (No. KPU260400-260421). Seven-week-old Wister rats (body weight 200–220 g) were housed in a 12-h light-dark cycle and allowed free access to standard rat chow and water. Rats were acclimatized for a week, divided into four groups, and were given 1 mL of glutathione-1,13C (50 mg/kg body weight) or NAC-1,13C (50 mg/kg body weight) once daily for 30 days. After 30 days, the rats were euthanized with an overdose of sodium pentobarbital by intraperitoneal injection and dissected under sterile conditions. Portions of the thoroughly washed intestines and livers were homogenized in the same volume of PBS containing 10 mM sodium phosphate buffer (pH 7.4) and 1 mM EDTA and the homogenates were then mixed with three fold volumes of PBS-2% 2-mercaptoethanol and allowed to stand for 2 h at 25°C. The supernatant was collected and used to determine the total amounts of glutathione and related peptides. Without 2-mercaptoethanol, the sulfhydryl group of glutathione was neutralized using 0.1 M sodium carbonate and filtered using a 0.45-μm filter (Cosmonice filter W, Nacalai Tesque). The filtrates were subjected to LC-MS/MS using a 3200 QTRAP system (AB SCIEX, Framingham, MA) as previously described.6

Without 2-mercaptoethanol, the sulfhydryl group of glutathione was conjugated with NEM in PBS. The NEM-glutathione derivative was directly subjected to LC-MS/MS to determine the reduced-form of glutathione. With NEM, glutathione disulfide was conjugated with two molecules of AccQs, and the resultant AccQ derivative of glutathione disulfide was subjected to the LC-MS/MS as described above. Reduced-form glutathione (2 nmol) was added to the ethanol-soluble fraction of plasma from portal blood. The recovery of the reduced-form glutathione was 82.5 ± 5.6%. Thus, the reduced form glutathione is stable under this condition and also matrix effect on ionization can be neglected. Endogenous glutathiones harboring either all 12C or one 13C in samples, which were collected before the ingestion of glutathione-1,13C, were determined. The ratio between endogenous glutathione containing one 13C and the total containing 13C ([R(13C/12C)]), was obtained. The content of food-derived glutathione was estimated by using the following equation: Food-derived glutathione content = (content of glutathione with one 13C in sample collected after ingestion) – [R(13C/12C)] × (content of glutathione with all 13C in sample collected after ingestion).

Statistics

Differences among the time points were evaluated using one-way analysis of variance (ANOVA) followed by Turkey’s test using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Differences between two groups were evaluated using t-test.

Data availability

All relevant data are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS

We would like to thank the Kyoto Integrated Science & Technology Bio-Analysis Center for allowing us to use their LC-MS/MS (3200 QTRAP) and Editage (www.editage.jp) for English language editing. This work was supported by grants from Kyoto Prefectural University, Kyoto University, and KOHIN Life Sciences.
AUTHOR CONTRIBUTIONS
Y.N. & K.S. designed the studies. The experiments were performed by H.Y., S.O., S.W., W.A., and E.Y.P. The manuscript was written by H.Y. & K.S.

ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Science of Food website (https://doi.org/10.1038/s41538-018-0011-y).

Competing interests: The authors declare no competing financial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Meister, A. & Anderson, M. E. Glutathione. Annu. Rev. Biochem. 52, 711–760 (1983).
2. Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R. & Turner, N. D. Glutathione metabolism and its implications for health. J. Nutr. 134, 489–492 (2004).
3. Arjnipathana, N. & Asawanonda, P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J. Dermatol. Treat. 23, 97–102 (2012).
4. Aoi, W. et al. Glutathione supplementation suppresses muscle fatigue induced by prolonged exercise via improved aerobic metabolism. J. Int. Soc. Sports Nutr. 12, 7 (2015).
5. Honda, Y. et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 17, 96 (2017).
6. Park, E. Y. et al. Increase in the protein-bound form of glutathione in human blood after the oral administration of glutathione. J. Agric. Food Chem. 62, 6183–6189 (2014).
7. Kovacs-Nolan, J. et al. In vitro and ex vivo uptake of glutathione (GSH) across the intestinal epithelium and fate of oral GSH after in vivo supplementation. J. Agric. Food Chem. 62, 9499–9506 (2014).
8. Kleinman, W. A. & Richie, J. P. Jr. Status of glutathione and other thiols and disulfides in human plasma. Biochem. Pharmacol. 60, 19–29 (2000).
9. Rahman, I., Kode, A. & Biswas, S. K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat. Protoc. 1, 3159–3165 (2006).
10. Carlberg, I. & Mannervik, B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J. Biol. Chem. 250, 5475–5480 (1975).
11. Viña, J., Perez, C., Furukawa, T., Palacin, M. & Viña, J. R. Effect of oral glutathione on hepatic glutathione levels in rats and mice. Br. J. Nutr. 62, 683–691 (1989).
12. Favilli, F. et al. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br. J. Nutr. 78, 293–300 (1997).
13. Gomez-Cabrera, M. C. et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am. J. Clin. Nutr. 87, 142–149 (2008).
14. Ristow, M. et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA 106, 8665–8670 (2009).
15. Zhang, D. D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug. Metab. Rev. 38, 769–789 (2006).